Corporate VCs have played a crucial role in financing life sciences companies for decades, but have you ever wondered what, if anything, makes them different from institutional venture capital funds? Join us for this webinar as we talk to a panel of investors at industry-leading CVC funds to learn more about their strategies, investment criteria, and how they measure success.
As 2019 came to a close, Pitchbook presented some deceptive data: VCs had invested a record high $17.2 billion in US-based startups with at least one female founder. While impressive upon first glance, look at these numbers from a different perspective: US-based startups that were founded solely by females only made up 6.7% of all VC deals and 2.7% by total capital invested. These percentages are all-time highs, but still very low compared to their male counterparts. And, what do the numbers look like for female academic founders? What can universities do to foster more female entrepreneurship?
While investments in biotech have reached record highs in recent years, investment in the diagnostics sector from traditional VCs has cooled. This is despite a rapid decline in the cost of sequencing and increased public interest in the potential of precision medicine. In this webinar, Osage University Partners explores the unique challenges facing diagnostics with Garheng Kong, a Managing Partner at HealthQuest Capital, a LabCorp director and active diagnostics investor, and Doug Fisher, CBO of Sera Prognostics and partner at InterWest Partners, also active in diagnostics.
The gender gap in academia at the faculty level has been well documented. Male faculty far outnumber women, particularly in the STEM disciplines, though the gap has narrowed in recent decades. It’s also no secret that the rate of academic entrepreneurship is on the rise: the number of startups formed out of university research has…